Comparative Pharmacology
Head-to-head clinical analysis: BACITRACIN NEOMYCIN POLYMYXIN W HYDROCORTISONE ACETATE versus KANTREX.
Peer-Reviewed Evidence
Head-to-head clinical analysis: BACITRACIN NEOMYCIN POLYMYXIN W HYDROCORTISONE ACETATE versus KANTREX.
BACITRACIN-NEOMYCIN-POLYMYXIN W/ HYDROCORTISONE ACETATE vs KANTREX
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Bacitracin inhibits bacterial cell wall synthesis by interfering with dephosphorylation of the peptidoglycan carrier lipid; neomycin binds to 30S ribosomal subunit causing misreading of mRNA; polymyxin B disrupts bacterial cell membrane permeability via interaction with phospholipids; hydrocortisone acetate suppresses inflammation by inhibiting phospholipase A2, reducing prostaglandin and leukotriene synthesis.
Aminoglycoside antibiotic that binds to the 30S ribosomal subunit, inhibiting bacterial protein synthesis and causing mRNA misreading.
Apply a thin layer to the affected area 3-4 times daily. Ophthalmic: Instill 1-2 drops into the affected eye(s) every 3-4 hours, or more frequently if needed. Otic: Instill 4 drops into the affected ear(s) 3-4 times daily.
15 mg/kg/day IM or IV divided every 8-12 hours (not to exceed 1.5 g/day)
None Documented
None Documented
Bacitracin: 1.5 h (systemic) but clinically irrelevant as topical. Neomycin: 2-3 h (systemic). Polymyxin B: 4.5-6 h (systemic). Hydrocortisone acetate: 1.5-2.5 h (plasma); clinical effect outlasts serum half-life due to intracellular activity.
2-3 hours (normal renal function); prolonged to 30-50 hours in anuria; clinically significant accumulation in renal impairment requires monitoring
Bacitracin: renal (minimal systemic absorption; eliminated unchanged in urine if absorbed). Neomycin: renal (90-95% excreted unchanged in urine after systemic absorption). Polymyxin B: renal (60% excreted unchanged over 24h; prolonged elimination in renal impairment). Hydrocortisone acetate: hepatic metabolism (glucuronidation, sulfation) and renal excretion of metabolites.
Renal: 80-100% as unchanged drug via glomerular filtration; fecal: <1%
Category A/B
Category C
Aminoglycoside Antibiotic
Aminoglycoside Antibiotic